Alto Neuroscience, Inc. Class Action Notice: ANRO Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Lawsuit

SAN DIEGO, Sept. 19, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired (a) Alto Neuroscience, Inc. (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering ("IPO") conducted on or about February 2, 2024, and/or (b) Alto securities between February 2, 2024 and October 22, 2024. Alto operates as a clinical-stage biopharmaceutical company in the U.S. The Company's product pipeline includes, inter alia, ALTO-100, which at the time of the IPO was in a Phase 2b clinical trial for the treatment of patients with major depressive disorder ("MDD").

Read more at prnewswire.com